Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Syndax Pharmaceuticals ( (SNDX) ) has shared an update.
On May 12, 2025, Syndax Pharmaceuticals announced the appointment of Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer, succeeding Dr. Neil Gallagher, who is stepping down. Dr. Botwood brings over 25 years of experience in oncology drug development from his previous roles at Bristol Myers Squibb and AstraZeneca. His appointment is expected to drive Syndax’s R&D strategy and accelerate the expansion of its oncology franchises. Additionally, on May 14, 2025, Syndax held its annual meeting of stockholders, where all proposals, including the election of directors, were passed.
The most recent analyst rating on (SNDX) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Syndax Pharmaceuticals stock, see the SNDX Stock Forecast page.
Spark’s Take on SNDX Stock
According to Spark, TipRanks’ AI Analyst, SNDX is a Neutral.
Syndax Pharmaceuticals faces significant risks due to declining revenues, persistent losses, and negative cash flows, which weigh heavily on its overall score. While the balance sheet remains strong with low leverage, the technical indicators suggest a bearish trend. The valuation is unattractive due to negative earnings. Despite these challenges, the recent earnings call provided some positive news with product launches and a strengthened financial position, partially offsetting the negative aspects. Overall, the company’s ability to improve financial performance and achieve market penetration in the face of competition will be crucial for future stock performance.
To see Spark’s full report on SNDX stock, click here.
More about Syndax Pharmaceuticals
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on advancing innovative cancer therapies. The company’s pipeline includes FDA-approved products such as Revuforj® (revumenib), a menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor. Syndax is committed to reimagining cancer care and is actively conducting clinical trials to expand its treatment offerings.
Average Trading Volume: 2,211,741
Technical Sentiment Signal: Sell
Current Market Cap: $798.5M
For detailed information about SNDX stock, go to TipRanks’ Stock Analysis page.